Multiple pathologies in a patient with a progressive neurodegenerative syndrome

Liang, T.-W.; Forman, M. S.; Duda, J. E.; McCluskey, I.; Trojanowski, J. Q.; Siderowf, A.
February 2005
Journal of Neurology, Neurosurgery & Psychiatry;Feb2005, Vol. 76 Issue 2, p252
Academic Journal
A woman presenting with levodopa responsive Parkinsonism developed rapidly progressive bulbar signs, quadriparesis, and upper and lower motor neurone signs. At necropsy, she was found to have three pothological diagnoses: amyotrophic lateral sclerosis, Parkinson's disease, and abundant tau-positive argyrophilic neuritic pathology, known as argyrophilic grain disease. This case raises the possibility that three distinct neuropathological diagnoses share a common aetiology.


Related Articles

  • Clinical: Managing Parkinson's disease in the long term. Rhind, George // GP: General Practitioner;3/24/2006, p47 

    The article presents information on options which can be used to treat Parkinson's disease. Parkinson's disease is a chronic progressive neuro-degenerative condition which results from dopaminergic neuronal loss in the substantia nigra. All patients should have the benefit of referral for the...

  • Madopar.  // Royal Society of Medicine: Medicines;2002, p344 

    This article presents information on Madopar, a proprietary, prescription-only compound preparation of levodopa and benserazide hydrochloride, which is a combination called co-beneldopa. It can be used to treat parkinsonism, but not the parkinsonian symptoms induced by drugs. It is available as...

  • Deep-brain stimulation for Parkinson's disease. Deuschl, G.; Fogel, W.; Hahne, M.; Kupsch, A.; Müller, D.; Oechsner, M.; Sommer, U.; Ulm, G.; Vogt, T.; Volkmann, J. // Journal of Neurology;Dec2002 Supplement 3, Vol. 249, piii36 

    Deep brain simulation (DBS) is a powerful new therapeutic approach for patients with Parkinson's disease. However, patient selection is critical for a valuable therapeutic result. Dopa sensitivity of the target symptoms, severe disability and low neurosurgical risks are among the major criteria...

  • The role of the long-duration response to levodopa in Parkinson's disease. Zappia, Mario; Nicoletti, Alessandra // Journal of Neurology;Nov2010, Vol. 257, p284 

    The long-duration response (LDR) to levodopa is an important component of the therapeutic response to the drug in Parkinson's disease (PD). Some characteristics are peculiar: it is independent from peripheral pharmacokinetics of levodopa, but it is dependent on the intervals between doses and on...

  • Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson’s patients. Stocchi, F.; Barbato, L.; Nordera, G.; Bolner, A.; Caraceni, T. // Journal of Neural Transmission;Feb2004, Vol. 111 Issue 2, p173 

    Summary. The aim of this trial was to evaluate the effects of the COMT inhibitor entacapone on both the pharmacokinetic profile and clinical efficacy of controlled release levodopa in Parkinson’s disease (PD) patients. Twelve PD patients experiencing ‘end-of-dose’ type motor...

  • Deep Brain Stimulation (DBS) attentional effects parallel those of l-dopa treatment. Brusa, L.; Pierantozzi, M.; Peppe, A.; Altibrandi, M. G.; Giacomini, P.; Mazzone, P.; Stanzione, P. // Journal of Neural Transmission;Sep2001, Vol. 108 Issue 8/9, p1021 

    Summary. Aim of our study was to investigate the different effects on attentional capacity of deep brain stimulation DBS (STN or GPi) and of l-dopa in PD patients. Patients were evaluated on-DBS/off-l-dopa, on-l-dopa/off-DBS, on-l-dopa/on-DBS and off-l-dopa/off-DBS. Our results indicate that DBS...

  • Postural Sway and Effect of Levodopa in Early Parkinson's Disease. Beuter, Anne; Hernández, Roberto; Rigal, Robert; Modolo, Julien; Blanchet, Pierre J. // Canadian Journal of Neurological Sciences;Mar2008, Vol. 35 Issue 1, p65 

    Objective: To characterize postural stability control and levodopa responsiveness in early Parkinson's disease (PD). Methods: Postural sway was studied during quiet stance in ten patients within six years of PD onset, both before (OFF) and after (ON) regular oral levodopa dosing. Postural sway...

  • Clinical advantages of COMT inhibition with entacapone - a review. Gordin, A.; Kaakkola, S.; Teräväinen, H. // Journal of Neural Transmission;Oct2004, Vol. 111 Issue 10-11, p1343 

    Two catechol-O-methyltransferase (COMT) inhibitors, entacapone and tolcapone, were developed during the 1990’s to be used as adjuncts to levodopa (LD) - dopa decarboxylase (DDC) inhibitors in the treatment of Parkinson’s disease (PD). Entacapone is currently in wide clinical use,...

  • The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson’s disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Wei-Li Kuan; Jing-Wei Zhao; Barker, Roger A. // Psychopharmacology;Apr2008, Vol. 197 Issue 2, p279 

    Levodopa-induced dyskinesia (LID) is an inevitable complication of the long-term treatment of Parkinson’s disease (PD) with levodopa. In a rat model of LID, we observed that animals of almost identical genetic but slightly different environmental backgrounds displayed a very different...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics